Safety and effectiveness of 8 weeks of Glecaprevir/Pibrentasvir in challenging HCV patients: Italian data from the CREST study
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0280165 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Alessio Aghemo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Hepatitis C. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie.
Abstract (Originalsprache)
Introduction
Glecaprevir/pibrentasvir (G/P) has demonstrated high rates (>95%) of sustained virologic response at posttreatment Week 12 (SVR12) in treatment-naïve (TN) patients with hepatitis C virus (HCV) infection and compensated cirrhosis (CC). Here, in a key real-world subset of TN Italian patients with CC, we evaluated the effectiveness and safety of 8-week G/P treatment, including subgroups of interest such as those with genotype 3 (GT3) infection, elderly patients, and those with more advanced liver disease.
Methods
Subanalysis of Italian patients enrolled in the CREST study. The full analysis set (FAS) included all patients enrolled in the study; the modified analysis set (MAS) excluded patients who discontinued G/P for nonvirologic failure or who had missing SVR12 results. Primary and secondary endpoints included SVR12 and safety, respectively.
Results
Of 42 patients included in the FAS, 1 discontinued for unknown reasons, and 2 had missing SVR12 data, leaving 39 patients included in the MAS. At treatment initiation, 74% of patients had ≥1 comorbidity, and 62% were receiving concomitant medications, including some that may potentially interact with G/P. SVR12 was achieved in 100% of patients in the MAS, and in 95% in the FAS. In subgroups of interest, the proportion of patients achieving SVR12 in the MAS (and FAS) was: 100% (94%) for patients ≥65 years, 100% (86%) for GT3, and 100% (100%) for patients with platelet count 20 kPa. Overall, 2 (5%) patients had an adverse event and neither were serious.
Conclusion
Results from this real-world Italian cohort demonstrated the safety and effectiveness of 8-week G/P, with SVR12 rate >95%, even in elderly patients. These findings further support real-world evidence of the use of short-course G/P treatment in all patients with CC, including those with GT3, and those with advanced liver disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
- Division of Internal Medicine and Hepatology, Humanitas Research Hospital IRCCS, Rozzano, Italy.
- Dipartimento di Medicina Clinica Medica, Epatologica e Lungodegenza, AOU OO. RR. San Giovanni di Dio Ruggi e D'Aragona, Salerno, Italy.
- Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- University of Tor Vergata, Rome, Italy.
- UC Gastroenterologia, Dipartimento di Specialità Mediche, Azienda Ospedaliera Universitaria di Modena, Modena, Italy.
ORCID-Profile: Alessio Aghemo
Förderung
- AbbVie
Zitieren
APA
Aghemo, A., Persico, M., D'Ambrosio, R., Andreoni, M., Villa, E., Bhagat, A., Gallinaro, V., Gualberti, G., Merolla, R. C. D., & Gasbarrini, A. (2023). Safety and effectiveness of 8 weeks of Glecaprevir/Pibrentasvir in challenging HCV patients: Italian data from the CREST study. PLOS ONE. https://doi.org/10.1371/journal.pone.0280165
Vancouver
Aghemo A, Persico M, D'Ambrosio R, Andreoni M, Villa E, Bhagat A, et al. Safety and effectiveness of 8 weeks of Glecaprevir/Pibrentasvir in challenging HCV patients: Italian data from the CREST study. PLOS ONE. 2023. doi:10.1371/journal.pone.0280165
BibTeX
@article{Aghemo2023,
author = {Aghemo, Alessio and Persico, Marcello and D'Ambrosio, Roberta and Andreoni, Massimo and Villa, Erica and Bhagat, Abhi and Gallinaro, Valentina and Gualberti, Giuliana and Merolla, Rocco Cosimo Damiano and Gasbarrini, Antonio},
title = {Safety and effectiveness of 8 weeks of Glecaprevir/Pibrentasvir in challenging HCV patients: Italian data from the CREST study},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0280165}
}
EUVIMED